Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Hormone Receptor-Positive Breast Carcinoma”

93 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 93 results

Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Not applicableStudy completedNCT01617954
What this trial is testing

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

Who this might be right for
Hormone Receptor Positive Malignant Neoplasm of Breast
Agendia 820
Not applicableEnded earlyNCT02149173
What this trial is testing

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Who this might be right for
Estrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
University of Washington 29
Early research (Phase 1)Study completedNCT02219789
What this trial is testing

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+3 more
Mayo Clinic 10
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Early research (Phase 1)Study completedNCT02088684
What this trial is testing

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 70
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Not applicableLooking for participantsNCT04476485
What this trial is testing

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Who this might be right for
Breast Cancer
Shengjing Hospital 1,000
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Testing effectiveness (Phase 2)Study completedNCT02015559
What this trial is testing

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerOral Complications+5 more
Jonsson Comprehensive Cancer Center 61
Testing effectiveness (Phase 2)Looking for participantsNCT07164976
What this trial is testing

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Nagoya City University 86
Testing effectiveness (Phase 2)Study completedNCT00082810
What this trial is testing

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerRecurrent Breast CancerStage IIIB Breast Cancer+2 more
National Cancer Institute (NCI) 33
Early research (Phase 1)Active Not RecruitingNCT01791478
What this trial is testing

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerInvasive Ductal Breast Carcinoma+3 more
Vanderbilt-Ingram Cancer Center 46
Testing effectiveness (Phase 2)Ended earlyNCT02273752
What this trial is testing

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerGastrinomaGlucagonoma+16 more
Emory University 2
Early research (Phase 1)Looking for participantsNCT07121244
What this trial is testing

68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Who this might be right for
Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast Cancer
Radionetics Oncology 62
Testing effectiveness (Phase 2)UnknownNCT04942899
What this trial is testing

Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer

Who this might be right for
Metastasis Breast
Assiut University 70
Early research (Phase 1)Looking for participantsNCT06745804
What this trial is testing

Study of 68Ga-R10602

Who this might be right for
Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast CancerHormone Receptor Positive Breast Adenocarcinoma
Radionetics Oncology 36
Large-scale testing (Phase 3)Active Not RecruitingNCT06635447
What this trial is testing

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Who this might be right for
Breast Cancer
AstraZeneca 258
Early research (Phase 1)Study completedNCT02820961
What this trial is testing

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor Positive Breast Cancer
Syndax Pharmaceuticals 61
Testing effectiveness (Phase 2)Study completedNCT00057941
What this trial is testing

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerProgesterone Receptor-positive Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 148
Load More Results